Question regarding an FDA guidance on topical dermatological Drug Product NDAs and ANDAs. ?

"For a topical solution drug product, in vivo bioequivalence may be waived if the inactive ingredients in the product are qualitatively (Q1 ) identical and quantitatively (Q2 ) essentially the...

24 April 2017 4,422 1 View